community acquired bacterial pneumonia cabp epidemiology forecast

• Community-acquired bacterial pneumonia (CABP) remains one of the most common and clinically significant lower respiratory tract infections worldwide. Among bacterial pathogens, Streptococcus pneumoniae is the leading and most prevalent causative organism globally, accounting for a substantial proportion of CABP cases and associated morbidity and mortality.
• Other notable pathogens responsible for CAP include Haemophilus influenzae and Mycoplasma pneumoniae. Notably, pneumonia caused by chlamydia and mycoplasma often presents similarly to other types of pneumonia, posing diagnostic challenges.
• In the US the annual incidence is 24.8 cases per 10,000 adults, with higher rates as age increases.
• Pneumonia is the eighth leading cause of death and first among infectious causes of death. The mortality rate is as high as 23% for patients admitted to the intensive care unit for severe pneumonia.
• The epidemiology of CABP varies geographically, with certain pathogens being more prevalent in specific regions. For example, coccidioidomycosis is more commonly observed in the Southwestern United States, while blastomycosis and histoplasmosis are endemic to the Ohio River Valley. Exposure to birds is associated with Chlamydia psittaci infection, whereas contact with flea-infested rodents or rabbits, particularly during outdoor activities in the Northeastern United States, is linked to tularemia pneumonia.
• Risk factors for CAP predominantly revolve around conditions impairing normal lung immunity mechanisms. Age constitutes the primary risk factor, with CAP incidence notably spiking in individuals over 65 years old. Consequently, CAP affects around 2% of those over 85 annually, as indicated by a recent British Thoracic Society (BTS) UK-wide audit where the average patient age was 76 years.

Community Acquired Bacterial Pneumonia (CABP) Epidemiology Forecast in the 7MM

• 2025 Incident Cases of Community Acquired Bacterial Pneumonia (CABP): ~XX million
• Community Acquired Bacterial Pneumonia (CABP) Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Community Acquired Bacterial Pneumonia Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Community Acquired Bacterial Pneumonia (CABP), historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Community Acquired Bacterial Pneumonia (CABP) Understanding and Diagnosis Algorithm

Community Acquired Bacterial Pneumonia (CABP) Overview

Community-acquired bacterial pneumonia (CABP) is an acute infection of the lung parenchyma acquired outside hospital settings, most commonly caused by pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and atypical organisms like Mycoplasma pneumoniae and Legionella pneumophila. It typically presents with symptoms such as fever, cough, sputum production, dyspnea, and chest pain, with severity ranging from mild illness to life-threatening disease, particularly in older adults and individuals with comorbidities. Diagnosis is based on clinical evaluation supported by chest imaging (e.g., chest X-ray showing infiltrates), microbiological testing (sputum culture, blood cultures, or PCR-based assays), and assessment of severity using validated scoring systems such as CURB-65, enabling timely and appropriate management.

Further details are provided in the report.

Community Acquired Bacterial Pneumonia (CABP) Epidemiology

Key Findings from Community Acquired Bacterial Pneumonia (CABP) Epidemiological Analysis and Forecast 

• Around 80% of the nearly 4 million cases of community-acquired pneumonia (CAP) in the US are classified as community-acquired bacterial pneumonia (CABP). This high prevalence of CABP within the broader category of CAP underscores the significant burden of bacterial pathogens in pneumonia cases. 
• In 2025, the US accounted for approximately 55% of the incidence cases of CABP among the 7MM. 
• In the US, mild cases of CABP constituted the highest proportion, approximately 50% of total incident cases, followed by moderate cases at around 35%. This distribution suggests that a significant majority of CABP cases are relatively less severe, possibly indicating effective early detection and outpatient management strategies.
• Among all the pathogens associated with CABP, Streptococcus pneumoniae stands out as the most common causative pathogen in the US, followed by other bacterial strains.  
• In 2025, gender-specific cases of Community-Acquired Bacterial Pneumonia (CABP) in the US showed that male individuals accounted for over half of the total CABP cases.
• CABP epidemiology in the US from 2022 to 2036 reveals a concerning trend of increasing cases for major pathogens. S. pneumoniae, H. influenzae, Staphylococcus aureus, M. pneumoniae, C. pneumoniae, and L. pneumophila are all projected to experience significant rises in cases.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of Community Acquired Bacterial Pneumonia (CABP), explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Community Acquired Bacterial Pneumonia (CABP) Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of Community Acquired Bacterial Pneumonia (CABP) ? What will be the growth opportunities across the 7MM concerning the patient population with Community Acquired Bacterial Pneumonia (CABP) ?
• What is the historical and forecasted Community Acquired Bacterial Pneumonia (CABP)  patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.